HK1182026A1 - Pharmaceutical dosage form comprising one or more antiretroviral active ingredients - Google Patents

Pharmaceutical dosage form comprising one or more antiretroviral active ingredients

Info

Publication number
HK1182026A1
HK1182026A1 HK13109455.4A HK13109455A HK1182026A1 HK 1182026 A1 HK1182026 A1 HK 1182026A1 HK 13109455 A HK13109455 A HK 13109455A HK 1182026 A1 HK1182026 A1 HK 1182026A1
Authority
HK
Hong Kong
Prior art keywords
dosage form
active ingredients
pharmaceutical dosage
antiretroviral active
antiretroviral
Prior art date
Application number
HK13109455.4A
Other languages
English (en)
Chinese (zh)
Inventor
.納拉瓦德
.謝迪
.拉維尚卡爾
.加德辛拉賈卡爾
.格裡茲克
.彼得萊特
.諾倫伯格
Original Assignee
贏創羅姆有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 贏創羅姆有限公司 filed Critical 贏創羅姆有限公司
Publication of HK1182026A1 publication Critical patent/HK1182026A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK13109455.4A 2010-05-10 2013-08-13 Pharmaceutical dosage form comprising one or more antiretroviral active ingredients HK1182026A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1306CH2010 2010-05-10
PCT/EP2011/053137 WO2011141192A1 (fr) 2010-05-10 2011-03-03 Forme posologique pharmaceutique comprenant un ou plusieurs principes actifs antirétroviraux

Publications (1)

Publication Number Publication Date
HK1182026A1 true HK1182026A1 (en) 2013-11-22

Family

ID=44115704

Family Applications (1)

Application Number Title Priority Date Filing Date
HK13109455.4A HK1182026A1 (en) 2010-05-10 2013-08-13 Pharmaceutical dosage form comprising one or more antiretroviral active ingredients

Country Status (8)

Country Link
US (1) US20130142877A1 (fr)
EP (1) EP2568964B1 (fr)
JP (1) JP2013526495A (fr)
CN (1) CN102985074B (fr)
CA (1) CA2799110A1 (fr)
ES (1) ES2688278T3 (fr)
HK (1) HK1182026A1 (fr)
WO (1) WO2011141192A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2866206A1 (fr) * 2012-03-07 2013-09-12 Ratiopharm Gmbh Forme galenique comprenant le lopinavir et le ritonavir
CA2871794A1 (fr) * 2012-05-03 2013-11-07 Cipla Limited Composition antiretrovirale
WO2015130083A1 (fr) * 2014-02-25 2015-09-03 동아에스티 주식회사 Composition pharmaceutique à usage amélioré contenant de l'entécavir
WO2015141662A1 (fr) * 2014-03-18 2015-09-24 武田薬品工業株式会社 Dispersion solide
CN105412975B (zh) * 2014-09-18 2019-05-31 苏州安德佳生物科技有限公司 一种生物相容性止血制品及其制备方法
US10034865B2 (en) 2015-09-10 2018-07-31 Kashiv Pharma, Llc Surfactant-free HIV protease inhibitor composition and method of manufacturing thereof
CA3022878C (fr) * 2016-05-09 2024-04-30 Dispersol Technologies, Llc Formulations de medicaments ameliorees
JP7378393B2 (ja) * 2017-11-10 2023-11-13 オースティンピーエックス リミテッド ライアビリティ カンパニー 改善された薬物製剤
ES2967689T3 (es) 2018-04-06 2024-05-03 Capsugel Belgium Nv Proceso de secado por aspersión para partículas de baja relación de aspecto que comprenden poli[(metacrilato de metilo)-co-(ácido metacrílico)]
EP3569225A1 (fr) * 2018-05-18 2019-11-20 Pharmaceutical Oriented Services Ltd Dispersion solide contenant du ritonavir
CN112206225A (zh) * 2020-07-16 2021-01-12 郑鉴忠 君臣佐使配伍的抗新冠病毒西药生产方法
CN113318076B (zh) * 2021-06-02 2022-09-23 聊城大学 一种兼具增溶及抑晶效果的利托那韦固体分散体及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3106449A1 (de) 1981-02-20 1982-09-09 Röhm GmbH, 6100 Darmstadt "in magensaft loesliche oder quellbare ueberzugsmasse und ihre verwendung in einem verfahren zum ueberziehen von arzneiformen"
EP0164669B1 (fr) 1984-06-13 1991-01-23 Röhm Gmbh Procédé pour enrober des formes pharmaceutiques
US6391338B1 (en) 1995-09-07 2002-05-21 Biovail Technologies Ltd. System for rendering substantially non-dissoluble bio-affecting agents bio-available
HUP0303700A3 (en) 2000-07-17 2006-07-28 Astellas Pharma Inc Chuo Ku Pharmaceutical composition improved in peroral absorbability
DE10239999A1 (de) * 2002-08-27 2004-03-04 Röhm GmbH & Co. KG Granulat oder Pulver zur Herstellung von Überzugs- und Bindemitteln für Arzneiformen
DE10304403A1 (de) 2003-01-28 2004-08-05 Röhm GmbH & Co. KG Verfahren zur Herstellung einer oralen Arzneiform mit unmittelbarem Zerfall und Wirkstofffreisetzung
US7273142B2 (en) 2004-02-17 2007-09-25 Sealed Air Corporation (Us) Packaging cushion delivery system
TW200815033A (en) 2006-08-10 2008-04-01 Cipla Ltd Antiretroviral solid oral composition
CA2669938C (fr) 2006-11-15 2016-01-05 Abbott Laboratories Formulations de dosage pharmaceutique solides
EP2279728A1 (fr) * 2009-07-31 2011-02-02 Ranbaxy Laboratories Limited Formes galéniques solides des inhibiteurs de la protéase du VIH

Also Published As

Publication number Publication date
EP2568964B1 (fr) 2018-08-01
CN102985074B (zh) 2015-09-02
CA2799110A1 (fr) 2011-11-17
US20130142877A1 (en) 2013-06-06
EP2568964A1 (fr) 2013-03-20
WO2011141192A1 (fr) 2011-11-17
CN102985074A (zh) 2013-03-20
ES2688278T3 (es) 2018-10-31
JP2013526495A (ja) 2013-06-24

Similar Documents

Publication Publication Date Title
HK1182026A1 (en) Pharmaceutical dosage form comprising one or more antiretroviral active ingredients
IL253870B (en) Certain amino-pyrimidines and pharmaceutical preparations containing them
ZA201304858B (en) Active ingredient combinations comprising pyridylethylbenzamides and other active ingredients
GB2569249C (en) Parasiticidal oral veterinary compositions comprising systemically-acting active agents and uses thereof
HK1182010A1 (en) Liquid pharmaceutical composition for the delivery of active ingredients
IL230463A (en) Benzamides, their preparation and their pharmaceutical preparations
FR2975004B1 (fr) Nouvel actif anti-rougeurs et compositions cosmetiques le comprenant
ZA201405949B (en) Pharmaceutical preparation containing and antivirally active dihydroquinazoline derivative
GB2486567B (en) Pharmaceutical formulation
HK1210767A1 (en) Pharmaceutical compositions comprising monoterpenes
HRP20180793T1 (hr) Farmaceutski pripravak i oblik doziranja koji sadrži dronedaron, te postupak njegove priprave
ZA201502695B (en) Stable pharmaceutical composition of peginterferon alpha-2b
HK1208188A1 (en) Formulations for the delivery of active ingredients
ZA201302012B (en) Low dose pharmaceutical composition
HRP20160928T1 (hr) Farmaceutske kompozicije koje sadrže anakinra bez citrata
IL226554A (en) Medicinal preparations containing alisporiovir
IL221087A (en) Pharmacy or nutritional composition
IT1399492B1 (it) Composizioni farmaceutiche effervescenti contenenti n-acetilcisteina.
EP2883546A4 (fr) Nouvelle composition pharmaceutique à libération différentielle contenant trois principes actifs
GB201216893D0 (en) Drug substance preparations, pharmaceutical compositions and dosage forms comprising s-(+)-flurbiprofen
ZA201201424B (en) Pharmaceutical dosage form
GB201110598D0 (en) Pharmaceutical compositions and devices